多西他赛联合奥沙利铂和FOLFOX4方案治疗晚期胃癌的临床研究

研究Clinical Study on Docetaxel Combined With Oxaliplatin and FOLFOX4 in the Treatment of Advanced Gastric Cancer

目的探析多西他赛联合奥沙利铂(DO)和FOLFOX4方案治疗晚期胃癌的临床效果及安全性。方法选取我院2013年1月—2014年12月收治的62例晚期初治胃癌患者,将其随机分为DO组和FOLFOX4组,各为31例,比较两组治疗效果及毒副作用。结果 DO组临床有效率为58.06%、临床获益率为83.87%,与FOLFOX4组比较,差异无统计学意义(χ~2=1.42,P>0.05);DO组KPS评分好转率为64.52%,与FOLFOX4组比较,差异无统计学意义(χ~2=1.33,P>0.05)。结论多西他赛联合奥沙利铂方案和FOLFOX4方案治疗晚期胃癌疗效相当。

Objective To investigate the clinical efficacy and safety of docetaxel combined with oxaliplatin （DO） and FOLFOX4 regimen in the treatment of advanced gastric cancer. Methods Sixty-two patients with newly diagnosed gastric cancer admitted from January 2013 to December 2014 in our hospital were randomly divided into DO group and FOLFOX4 group, with 31 cases in each group. The therapeutic effects and side effects were compared between the two groups. Results The clinical effective rate was 58.06% and the clinical beneft rate was 83.87% in DO group. There was no signifcant difference between DO group and FOLFOX4 group （χ2=1.42, P 〉 0.05）. The improvement rate of KPS score in DO group was 64.52% .There was no signifcant difference between DO group and FOLFOX4 group （χ2=1.33, P 〉 0.05）. Conclusion Docetaxel and oxaliplatin combined with FOLFOX4 regimen for the treatment of advanced gastric cancer have comparable effcacy.